Phase 1/2 Clinical Study of TPX-115 in Patients With Partial-Thickness Rotator Cuff Tear

Phase 1

Completed

• Conditions: Rotator Cuff Injuries
• Interventions: Biological: TPX-115; Other: Placebo

• Registration Number: NCT04470167
• Lead Sponsor: Tego Science, Inc.

Brief Summary

Rotator cuff tear is one of the most common shoulder diseases and conservative treatment is commonly used for tears involving ≤50% of tendon thickness. Since conventional conservative treatments are not fundamental to repair tendon tissue, there is a growing need of new therapy to improve structural outcome. This study assesses the safety and efficacy of allogeneic fibroblasts on partial-thickness rotator cuff tear. The primary outcome is change in American Shoulder and Elbow Surgeons (ASES) score at 24 weeks after TPX-115 injection. Secondary outcomes include changes from baseline in Visual Analogue Score (VAS) pain score, functional evaluations including Range of Motion (ROM), Constant Score (CS), ASES score and Simple Shoulder Test (SST) at 4, 12 and 24 weeks after administration and structural evaluation using MRI at 24 weeks after injection.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-03
• Study First Submitted QC: 2020-07-13
• Study First Posted: 2020-07-14
• Study Start: 2020-10-26
• Primary Completion: 2022-02-17
• Study Completion: 2022-02-17
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-17
• Last Update Posted: 2023-05-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

Participants must;

1. Be 19 years of age or older.
2. Have partial-thickness rotator cuff tear, ≤50% of tendon thickness or of Ellman grade I, II assessed by MRI.
3. Have unilateral shoulder pain lasting more than 3 months despite conservative treatment and VAS pain score ≥5 at screening.
4. Understand fully the study and voluntarily sign the informed consent for participation in the study.

Exclusion Criteria

Participants with any of the following conditions will be excluded unless stated otherwise;

1. Have partial-thickness rotator cuff tear larger than 50% of tendon thickness or of Ellman grade III, or full-thickness rotator cuff tear confirmed by MRI.

2. Have prior medical history of shoulder surgery on the torn rotator cuff or the upper part of shoulder within 6 months prior to screening visit (shoulder trauma, fracture, upper cervical spine surgery, etc.).

3. Have had subacromial or intra-articular injections on the affected shoulder within 3 months prior to screening visit.

4. Have had received systemic steroid or immunosuppressive agents within 4 weeks prior to screening visit.

5. Have been diagnosed with the following diseases.

   • Inflammatory joint diseases
   • Other shoulder diseases which may cause shoulder pain or functional disorder
   • Autoimmune diseases
   • Active hepatitis B or C
   • HIV Ab positive
   • Malignant tumors within the last 5 years
   • Coagulopathy
   • Genetic disorders related to fibroblasts of collagen
   • Other serious diseases deemed to affect the results of the study

6. Have allergies to bovine proteins or gentamicin.

7. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptive suggested in this study.

8. Have participated in other clinical trials and received investigational agents within 4 weeks of this study

9. Be deemed inadequate for the study by investigators.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TPX-115	TPX-115	Subjects receive ultrasound-guided intratendinous injection of TPX-115
Placebo	Placebo	Subjects receive ultrasound-guided intratendinous placebo injection

Primary Outcome Measures

Name	Time	Method
Change in shoulder score of American Shoulder and Elbow Surgeons (ASES)	24 weeks	ASES shoulder score is derived from the Visual Analogue Scale (VAS) score for pain and activities of daily living score. The total score - maximum of 100 points - is weighted 50% for pain and 50% for function.

Secondary Outcome Measures

Name	Time	Method
Change in tear/footprint on MRI	24 weeks	Ratio of tear lengths to whole footprint length is measured by an independent evaluator.
Change in shoulder score of American Shoulder and Elbow Surgeons (ASES)	4, 12 weeks	ASES shoulder score is derived from the Visual Analogue Scale (VAS) score for pain and the activities of daily living score. The total score - maximum of points - is weighted 50% for pain and 50% for function.
Change in Range of Motion (ROM)	4, 12, 24 weeks	Measurement of ROM for forward elevation, external rotation at 90º abduction, external rotation at side and internal rotation at back.
Change in pain score of Visual Analogue Scale (VAS)	4, 12, 24 weeks	VAS pain score is measured on a scale of 0 (no pain) to 10 (worst pain imaginable).
Change in Constant score (CS)	4, 12, 24 weeks	The CS total score (100) = Pain (15) + Activity of Daily Living (20) + Mobility (40) + Strength(25)
Change in Simple Shoulder Test (SST) Score	4, 12, 24 weeks	SST assesses functional disability of the shoulder (function related to pain, function/strength and Range of Motion).
Change in tear size on Magnetic Resonance Image (MRI)	24 weeks	Tear size is assessed by an independent evaluator.
Change of tendinosis on MRI	24 weeks	Tendinosis is assessed with tendinosis grading system by an independent evaluator. (0: normal, 1: mild, 2: moderate, 3: marked)
Change in tendon thickness on Magnetic Resonance Image (MRI)	24 weeks	Tendon thickness is assessed by an independent evaluator.

Trial Locations

Locations (2)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of